APOPWのニュース
Explore Volume Patterns For Some Important Insights: Ardelyx, Inc. (NASDAQ:ARDX), Cellect Biotechnology Ltd. (NASDAQ:APOP) 2021/07/20 21:41:57 Stock Equity
Ardelyx, Inc. (NASDAQ:ARDX) with the stream of -73.96% also noticed, India Cellect Biotechnology Ltd. (NASDAQ:APOP) encountered a rapid change of -1.90% in the last hour of Tuesdays trading session. Ardelyx, The post Explore Volume Patterns For Some Important Insights: Ardelyx, Inc. (NASDAQ:ARDX), Cellect Biotechnology Ltd. (NASDAQ:APOP) appeared first on Stocks Equity .
Attention Seeking Stock: Meta Materials Inc. (NASDAQ:MMAT), Cellect Biotechnology Ltd. (NASDAQ:APOP) 2021/07/14 20:50:52 Stock Equity
Meta Materials Inc. (MMAT) with the stream of -1.50% also noticed, India Cellect Biotechnology Ltd. (APOP) encountered a rapid change of 4.69% in the last hour of Wednesdays trading session. The post Attention Seeking Stock: Meta Materials Inc. (NASDAQ:MMAT), Cellect Biotechnology Ltd. (NASDAQ:APOP) appeared first on Stocks Equity .
34 Stocks Moving In Thursday''s Mid-Day Session 2021/06/17 16:03:13 Benzinga
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP ) shares jumped 68.5% Full story available on Benzinga.com
Cellect Registers Merger Agreement 2021/06/17 14:10:00 Baystreet Canada
Cellect Biotechnology Ltd. (NASDAQ:APOP) shares rose Thursday, having filed registration statement in connection with proposed strategic merger agreement with Quoin Pharmaceuticals. The Israel-based Cellect, a developer of innovative technology that enables the functional selection of stem cells, announced today that it has filed a registration statement, including a joint proxy statement/prospectus, with the Securities and Exchange Commission (SEC) in connection with its proposed strategic merger with privately-held Quoin Pharmaceuticals. Quoin is a specialty pharmaceutical company focused on rare and orphan diseases. Quoins leadership team is made up of industry veterans, with extensive relevant executive experience and proven records of recent success in the pharmaceutical industry. The transaction is currently expected to close in the 2021 third quarter. The Company believes the progress of Quoins clinical programs, and the secured investments of $25.5 million, will benefit and maximize Cellect shareholders.
Cellect Bio soars 57% after filing registration statement for Quoin Pharma merger 2021/06/17 05:20:37 Seeking Alpha
Explore Volume Patterns For Some Important Insights: Ardelyx, Inc. (NASDAQ:ARDX), Cellect Biotechnology Ltd. (NASDAQ:APOP) 2021/07/20 21:41:57 Stock Equity
Ardelyx, Inc. (NASDAQ:ARDX) with the stream of -73.96% also noticed, India Cellect Biotechnology Ltd. (NASDAQ:APOP) encountered a rapid change of -1.90% in the last hour of Tuesdays trading session. Ardelyx, The post Explore Volume Patterns For Some Important Insights: Ardelyx, Inc. (NASDAQ:ARDX), Cellect Biotechnology Ltd. (NASDAQ:APOP) appeared first on Stocks Equity .
Attention Seeking Stock: Meta Materials Inc. (NASDAQ:MMAT), Cellect Biotechnology Ltd. (NASDAQ:APOP) 2021/07/14 20:50:52 Stock Equity
Meta Materials Inc. (MMAT) with the stream of -1.50% also noticed, India Cellect Biotechnology Ltd. (APOP) encountered a rapid change of 4.69% in the last hour of Wednesdays trading session. The post Attention Seeking Stock: Meta Materials Inc. (NASDAQ:MMAT), Cellect Biotechnology Ltd. (NASDAQ:APOP) appeared first on Stocks Equity .
34 Stocks Moving In Thursday''s Mid-Day Session 2021/06/17 16:03:13 Benzinga
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP ) shares jumped 68.5% Full story available on Benzinga.com
Cellect Registers Merger Agreement 2021/06/17 14:10:00 Baystreet Canada
Cellect Biotechnology Ltd. (NASDAQ:APOP) shares rose Thursday, having filed registration statement in connection with proposed strategic merger agreement with Quoin Pharmaceuticals. The Israel-based Cellect, a developer of innovative technology that enables the functional selection of stem cells, announced today that it has filed a registration statement, including a joint proxy statement/prospectus, with the Securities and Exchange Commission (SEC) in connection with its proposed strategic merger with privately-held Quoin Pharmaceuticals. Quoin is a specialty pharmaceutical company focused on rare and orphan diseases. Quoins leadership team is made up of industry veterans, with extensive relevant executive experience and proven records of recent success in the pharmaceutical industry. The transaction is currently expected to close in the 2021 third quarter. The Company believes the progress of Quoins clinical programs, and the secured investments of $25.5 million, will benefit and maximize Cellect shareholders.